Table 1.

Variations in disease activity measures in patients with comorbidities (MD)

Comorbidity	SJC28	TJC28	ESR	PtGA	PhGA	HAQ	Fatigue	DAS28	CDAI

Hypertension	−0.15	−0.11	1.40	0.25	0.10	0.06	0.19	0.06	0.05
Diabetes	1.06	0.93	1.75	0.54	0.53	0.07	0.61	0.34	3.09
Dyslipidemia	−0.77	−0.56	−3.56	−0.35	−0.31	−0.05	−0.01	−0.30	−2.04
Renal deficiency	−0.19	0.90	4.70	0.13	0.61	0.13	0.17	0.28	1.76
Ischemic heart disease	0.39	1.27	5.64	0.48	0.42	0.16	0.59	0.40	2.61
Stroke	−0.21	0.12	3.85	−0.42	−0.20	0.21	0.66	−0.03	−1.02
Cancer disease	−0.19	−0.33	−0.74	0.55	0.13	0.04	0.45	−0.05	0.12
Gastro-intestinal ulcers	−0.36	−0.25	0.92	0.20	−0.14	0.09	0.41	0.02	−0.59
Hepatitis	0.50	0.31	0.41	0.16	−0.09	0.00	0.16	0.13	0.83
Depression	−0.41	−0.04	−3.20	0.20	0.02	0.12	0.47	−0.08	−0.16
Chronic pulmonary disease	−0.01	0.17	−1.27	0.47	0.09	0.07	0.39	0.08	0.66
Obesity	0.10	1.07	5.20	0.17	0.20	0.13	0.33	0.34	1.64

All models adjusted for age, gender, treatments (corticosteroids, NSAIDs, DMARDs), disease duration, serology and other comorbidities. Statistically significant MD (P<0.05) in bold.